HPLC-UV Method for Determination of Famotidine from Pharmaceutical Products

Nita, Adriana; Ţiţ, Delia Mirela; Copolovici, Lucian; Melinte, Carmen Elena; Copolovici, Dana; Bungău, Simona; Iovan, Ciprian

doi:10.37358/rc.18.2.6093

Cited by 8 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All solutions were filtered using a 0.22 µm syringe filter, and then 10 µL was exposed to HPLC analysis using Waters-2690 Alliance® HPLC system (Waters TM, Milford, MA, USA). HPLC conditions were in mobile phase: Water: Methanol: Acetonitrile (30%:60%:10%) and flow rate: 1 mL/min [ 53 ]. A distinct peak of the drug was observed at 300 nm.…”

Section: Methodsmentioning

confidence: 99%

Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability

et al. 2022

View full text Add to dashboard Cite

VEGF plays a crucial role in cancer development, angiogenesis and progression, principally liver and breast cancer. It is vital to uncover novel chemical candidates of VEGFR inhibitors to develop more potent anti-breast and anti-liver cancer agents than the currently available candidates, sorafenib and regorafenib, that face resistance obstacles and severe side effects. Herein, nine pyrazolopyrimidine derivatives were designed, synthesized as sorafenib and regorafenib analogues and screened for their in vitro cytotoxic and growth inhibition activities against four human cancer cell lines, namely breast cancer (Michigan Cancer Foundation-7 (MCF-7), hepatocellular carcinoma (HCC) type (HepG2), lung carcinoma (A-549) and human colorectal carcinoma-116 (HCT-116)). Among the tested compounds, compounds 1, 2a, 4b and 7 showed the uppermost cytotoxic activities against all aforementioned cell lines with IC50 estimates varying from 6 to 50 µM, among which compound 7 showed the best inhibitory activity on all tested compounds. Stunningly, compound 7 showed the best significant inhibition of the VEGFR-2 protein expression level (72.3%) as compared to the control and even higher than that produced with sorafenib and regorafenib (70.4% and 55.6%, respectively). Modeling studies provided evidence for the possible interactions of the synthesized compounds with the key residues of the ATP binding sites on the hinge region and the “DFG out” motif of VEGFR-2 kinase. Collectively, our present study suggests that pyrazolopyrimidine derivatives are a novel class of anti-cancer drug candidates to inhibit VEGF-VEGFR function. Aspiring to promote constrained aqueous solubility, hence poor oral bioavailability of the developed lead molecule, 7 and 2a-charged D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) surface-coated niosomes were successfully constructed, adopting a thin film hydration technique striving to overcome these pitfalls. A 23 full factorial design was involved in order to investigate the influence of formulation variables: type of surfactant, either Span 60 or Span 40; surfactant:cholesterol ratio (8:2 or 5:5) along with the amount of TPGS (25 mg or 50 mg) on the characteristics of the nanosystem. F2 and S2 were picked as the optimum formula for compounds 2a and 7 with desirability values of 0.907 and 0.903, respectively. In addition, a distinguished improvement was observed in the compound’s oral bioavailability and cytotoxic activity after being included in the nano-TPGS-coated niosomal system relative to the unformulated compound. The nano-TPGS-coated niosomal system increased the hepatocellular inhibitory activity four times fold of compound 7a (1.6 µM) and two-fold of 2a (3 µM) relative to the unformulated compounds (6 µM and 6.2 µM, respectively).

show abstract

Section: Methodsmentioning

confidence: 99%

Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Relative standard deviation (coefficient of variation) RSD % has been investigated : RSD % = (SD x 100)/ X average (9), whereas X average was represented the mean of measured absorbances. For accurate measurements, RSD ≤ 5% [8,[18][19][20]. To analyze the stability in time, a reference sample solution (5 µg/mL) was selected from standard solutions set, and was investigated during 32 h at room temperature, in normal conditions storage.…”

Section: Linearity Of the Method Regression Line Parametersmentioning

confidence: 99%

Visible Spectrophotometric Analysis Method of Sodium Metamizole in Tablets

Gavat¹,

Vasilescu²,

Marculescu³

2019

Rev. Chim.

View full text Add to dashboard Cite

The aim of this research was to exactly quantify pure sodium metamizole from tablets , using a spectrophotometric analysis in Visible range. The method applied has been subjected to a validation protocal which consisted in analyzing the following parameters: linearity of the method, detection limit (LD) , quantitation limit (LQ), Sandell�s sensitivity, interference of excipients, stability of prepared solutions, method and system precision, accuracy of the method. Following actual dosing, pure sodium metamizole amount in tablet of pharmaceutical was found to be 477.477 mg assigned to a percentage content of 95.495 %, very close to official declared amount (500 mg), with an maximum average percentage deviation of only 4.505 % from the official declared active substance content. This value was situated below the maximum admissible percentage deviation from stated active substance content (� 5%), established by Romanian Pharmacopoeia, X-th Edition rules.

show abstract

“…Quantitative estimation of the drug in tested microspheres was performed using a laboratory HPLC reference method, using Agilent 1100 Series HPLC (Agilent Technologies, Waldron, Germany). The separation was carried out on C18 (4.6 mmX150 mm) column filled with 5μ Equisil BDS, and the elution solvent consisted of a filtered and degassed mixture of methanol and 1% acetic acid aqueous solution in the ratio of 30:70 (v/v), at a flow rate of 0.4 ml/min [22].…”

Section: Estimation Of Famotidine By Hplcmentioning

confidence: 99%

Preparation and Evaluation of Once-Daily Floating Gmo-Alginate Microspheres Containing Famotidine

et al. 2023

View full text Add to dashboard Cite

Objective: In this work, a gastro-retentive floating microsphere delivery system composed of Drug/Glyceryl mono-oleate (GMO) embedded in a Ca-alginate gas-generated matrix was designed to improve the bioavailability of a slightly-soluble model drug Famotidine. Methods: The water/Oil emulsion method was used to prepare Famotidine floatable microspheres, and formulation variables such as Alginate: GMO ratio, gas-generated bicarbonates concentration, and loading drug concentration were investigated. Conventional techniques, including DSC, XRD and FTIR were performed to confirm Famotidine compatibility with GMO and Alginate polymers. Real-Time X-ray Radiography was used for in vivo imaging of Famotidine floatable microspheres using rabbits as an animal model. HPLC spectroscopic technique was used to determine Famotidine plasma concentration after oral administration of Alginate-GMO loaded microspheres. Results: Floating Famotidine Alginate-GMO microspheres (0.75:1:0.25) w/w/w showed a remarkable entrapment efficiency (>98%), good buoyancy (>84) and prolonged in vitro drug release properties (>24 hours). DSC, XRD, and FTIR techniques showed no evidence of interaction between Famotidine and Alginate or GMO. In vivo Imaging of Famotidine floatable microspheres showed that capsules containing Famotidine-Alginate microspheres were not detected after 3 h of administration, while capsules containing Famotidine-GMO-Alginate microspheres can be detected for more than 12 h, indicating superior gastric retention properties. The pharmacokinetic parameters were calculated for Famotidine: GMO-Alginate, and Famotidine: alginate and compared with the plain drug over 24 h period. Famotidine: GMO-Alginate microspheres exhibited controlled and prolonged absorption Tmax of 6.0 vs. 3.0 and 2.0 h; Cmax of 124.9±0.9 vs. 323.7±0.4and 458.6±0.5 ng/ml; AUC0-24 of 2153.025±6.7 vs. 1650.4±1.9 and 1110.725±2.1 ng/ml for Famotidine: alginate and plain drug, respectively, reflecting the increase in the bioavailability of the drug in the floating formulations compared to the free drug. Conclusion: Prolonged gastric retention time and sustained release properties of floating GMO-alginate microsphere suggest that it could provide a valuable sustained release dosage form of slightly-soluble drugs.

show abstract

HPLC-UV Method for Determination of Famotidine from Pharmaceutical Products

Cited by 8 publications

References 14 publications

Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability

Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability

Visible Spectrophotometric Analysis Method of Sodium Metamizole in Tablets

Preparation and Evaluation of Once-Daily Floating Gmo-Alginate Microspheres Containing Famotidine

Contact Info

Product

Resources

About